Multinational Pharma Companies Accelerate Value Realization in China with Multiple New Drug Approvals

　　【Pharmaceutical Network | Industry Dynamics】In recent years, innovative reforms in China's pharmaceutical industry have continued to deepen, with the drug evaluation and approval system being continuously optimized and the innovation ecosystem growing increasingly robust. This has attracted global multinational pharmaceutical companies to steadily increase their investments and expand their presence in the Chinese market. Recently, leading international pharmaceutical companies such as Johnson & Johnson, Boehringer Ingelheim, and Eli Lilly have successively announced the approval of their new drugs in China.
 

For example, Johnson & Johnson recently announced that its fully human neonatal Fc receptor (FcRn) antagonist, Anliwe (nipocalimab injection), has been approved by the National Medical Products Administration (NMPA) for use in combination with standard therapy for the treatment of generalized myasthenia gravis.
 

Generalized myasthenia gravis (gMG) is a chronic, autoimmune rare disease in which abnormal IgG antibodies attack the neuromuscular junction, leading to typical symptoms such as muscle weakness and fatigability. In severe cases, it may involve the swallowing and respiratory muscles, posing a life-threatening risk. Nicalizumab Injection is a fully human neonatal Fc receptor (FcRn) antagonist and a novel-mechanism therapeutic agent for myasthenia gravis approved in China. This medication effectively reduces pathogenic IgG antibody levels in patients, targeting the underlying disease mechanism. Furthermore, it does not interfere with the body's normal adaptive and innate immune responses, enabling stable disease control and improved quality of life, while providing a new treatment pathway for patients with refractory disease, special subtypes, and pediatric cases.
 

A representative from Johnson & Johnson stated that the launch of Anliwei marks a pivotal step in the company's commitment to advancing rare disease therapies. This medication provides sustained and stable disease control for a broad population of myasthenia gravis patients, promising to enhance their treatment experience and help them regain autonomy over their daily lives. We look forward to this innovative therapy reaching more patients in China as soon as possible, empowering them to reclaim their health and hope. It is reported that the drug is indicated for use in combination with standard-of-care therapies for the treatment of adult and adolescent patients (aged 12 years and older) with generalized myasthenia gravis who test positive for anti-acetylcholine receptor (AChR) antibodies or anti-muscle-specific kinase (MuSK) antibodies, thereby introducing a new approved treatment option for this patient population in China.
 

Boehringer Ingelheim and Sino Biopharm recently jointly announced that Shenghetu® (Chinese generic name: zongertinib tablets; English generic name: zongertinib), co-promoted in mainland China by the two parties, has been approved by China's National Medical Products Administration (NMPA) as a monotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring HER2 (ERBB2) tyrosine kinase domain activating mutations.
 

The approval of the first-line indication for Shenghetu®, an oral HER2 tyrosine kinase inhibitor, marks the official entry of China’s HER2-mutant advanced non-small cell lung cancer (NSCLC) into a new era of precision first-line targeted therapy. It ends the long-standing lack of highly effective and precise targeted drugs for first-line treatment in this patient population, while its oral administration route also offers greater convenience to patients.
 

Eli Lilly China recently announced that the combination therapy of ELUNATE (fruquintinib) and TYVYT (sintilimab injection) has been approved by China's National Medical Products Administration for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have experienced disease progression following prior treatment with a vascular endothelial growth factor receptor-tyrosine kinase inhibitor ("VEGFR-TKI") and have not previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor in the first-line setting.
 

Data show that globally, an estimated 435,000 new cases of kidney cancer were diagnosed in 2022. In China, an estimated 74,000 new cases were reported in 2022. Renal cell carcinoma (RCC) accounts for approximately 90% of all kidney cancer cases. The approval of the new indication for fruquintinib in combination with sintilimab marks a significant breakthrough in the treatment of renal cell carcinoma, underscoring the value of cross-company collaborative innovation in accelerating the translation of scientific research outcomes to benefit patients.
 

Behind the rapid succession of approvals for multiple new drugs lies the continuous refinement of China's pharmaceutical innovation policy framework. Innovative regulatory mechanisms, including priority review and breakthrough therapy designation, have substantially shortened the timeline for overseas innovative drugs to enter the Chinese market. Meanwhile, China's increasingly mature biopharmaceutical supply chain and comprehensive supporting infrastructure have provided a solid foundation for multinational pharmaceutical companies to localize production and engage in joint R&D. Looking ahead, as China's pharmaceutical market continues to open and its innovation ecosystem is further optimized, more global blockbuster drugs are expected to launch in China.
 

Disclaimer: Under no circumstances shall the information contained herein or any opinions expressed constitute investment advice to any person.